Approximately 30% to 40% of hospitalized patients with acute coronary syndrome are older adults, among whom the majority of cardiovascular-related deaths occur. When compared to younger patients, these individuals generally experience inferior clinical outcomes. Most clinical trials assessing the efficacy and safety of various therapeutics have primarily enrolled patients under the age of 75, in addition to excluding those with geriatric complexities. In this review, we emphasize the need for a personalized and comprehensive approach to pharmacotherapy for coronary heart disease and acute coronary syndrome in older adults, considering concomitant geriatric syndromes and age-related factors to optimize treatment outcomes while minimizing potential risks and complications. In the realm of clinical practice, cardiovascular and geriatric risks are closely intertwined, with both being significant factors in determining treatments aimed at reducing negative outcomes and attaining health conditions most valued by older adults.
Keyphrases
- acute coronary syndrome
- end stage renal disease
- clinical trial
- coronary artery disease
- ejection fraction
- newly diagnosed
- physical activity
- chronic kidney disease
- public health
- human health
- percutaneous coronary intervention
- prognostic factors
- randomized controlled trial
- antiplatelet therapy
- metabolic syndrome
- patient reported outcomes
- insulin resistance
- adipose tissue
- health information
- patient reported
- phase iii
- weight loss
- open label
- aortic valve